Short- and Long-Term Effects on Glucose Control of Nonadherence to Insulin Therapy in People With Type 2 Diabetes An In Silico Study

• Published in: Journal of diabetes science and technology Vol. 18; no. 2; pp. 309 - 317
• Main Authors: Visentin, Roberto, Cobelli, Claudio, Sieber, Jochen, Dalla Man, Chiara
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.03.2024
• Subjects: Blood Glucose; Diabetes Mellitus, Type 2 - drug therapy; Glucose; Humans; Insulin; Insulin, Regular, Human; Special Section: Algorithms for Predicting Complications of Diabetes; computer simulation; modeling; diabetes complications; diabetes control
• ISSN: 1932-2968; 1932-3107; 1932-3107
• DOI: 10.1177/19322968231223936

Background: Strict adherence to multiple daily insulin (MDI) therapy is a cornerstone for the achievement of good glucose control in people with advanced type 2 diabetes (T2D). Here, we aim to in silico assess glucose control in T2D subjects with poor adherence to MDI therapy. Methods: We tuned the Padova T2D Simulator, originally describing early-stage T2D physiology, around advanced T2D people. One hundred in silico advanced T2D subjects were generated and equipped with optimal MDI therapy: specifically, basal and bolus insulin amounts and injection times were individualized for each subject by applying titration algorithms that iteratively update insulin dose based on glucose deviation from its target. Then, the effect of nonadhering to MDI therapy was assessed using standard glucose control metrics calculated in two 6-month 3-meal/day in silico scenarios: in Scenario 1, subjects received the optimal basal and prandial insulin bolus at each meal; in Scenario 2, subjects received optimal basal insulin and randomly delayed or skipped the prandial insulin bolus in 3 lunches during working days and 1 dinner during weekends. Results: A statistically significant degradation was found in all glucose control outcome metrics in Scenario 2 versus Scenario 1: e.g., percent time above 180 mg/dL increased by 22.2% and glucose management index by 0.2%. Conclusions: Impaired adherence to MDI therapy in T2D leads to glucose control deteriorations in both short and long terms. Interestingly, short-term hyperglycemia seems being contrasted by residual endogenous insulin secretion, which statistically increased by 3-fold after delayed/skipped insulin boluses compared with optimal ones.